Aptar Pharma hosts “The Nasal drug Delivery Journey: From Systemic to Nose-to-Brain" scientific webinar
![](/46/pdcnewsitem/04/26/59/aptar.jpg)
Webinar will focus on the nasal drug delivery route in the treatment of central nervous system diseases.
Aptar Pharma will host an online scientific event focused on the nasal drug delivery route in the treatment of central nervous system (CNS) diseases. The panel will be composed of our experts, Pierre Carlotti and Gerallt Williams (Aptar Pharma), and Julie Suman (Next Breath). Participants may join this webinar on 8 September (4 PM – Paris time/10 AM New York time).
The webinar will be presented live and will include interactive exchanges with registered participants.
The Aptar Pharma webinar will feature discussions on the following topics:
• Unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases
• Drug transport into the CNS via the nasal route
• Nasal drug delivery devices that target CNS-related diseases
• New opportunities in areas such as nose-to-brain drug delivery.
By 2030, one billion people worldwide will be over the age of 65 compared to 600 million today. Healthcare must adjust to these changing demographics. In addition, the world is facing multiple unmet medical needs.
Several changes - new therapeutic options, shorter hospital stays, increased outpatient care and more self-administration of drugs, to name a few – are imperative within a short time frame. The pharmaceutical and biotech industries are striving to provide affordable solutions to these challenges.
This environment provides a wide range of opportunities for the CNS drug market ($145 billion in 2015) in the future treatment of patients. Covering areas such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, migraine, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety and bipolar disorders, new CNS drug delivery options will benefit patients and enhance overall healthcare.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance